Search Results - "Olszewski, Adam J"

Epidemiology and survival outcomes of ocular and mucosal melanomas: A population‐based analysis by Bishop, Kenneth D., Olszewski, Adam J.

“…Extracutaneous melanomas are poorly characterized tumors that include ocular (OM), mucosal (MM) and leptomeningeal melanomas, often lacking standardized…”
Get full text

Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia by LeBlanc, Thomas W., Egan, Pamela C., Olszewski, Adam J.

“…Hospice provides high-quality end-of-life care, but patients with leukemias use hospice services less frequently than those with solid tumors. Transfusion…”
Get full text

Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients by Di, Mengyang, Huntington, Scott F, Olszewski, Adam J.

“…Most patients with diffuse large B‐cell lymphoma (DLBCL) are diagnosed at age 60 years or older. Challenges to effective therapy among older individuals…”
Get full text

Defining and treating high-grade B-cell lymphoma, NOS by Olszewski, Adam J., Kurt, Habibe, Evens, Andrew M.

“…High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes…”
Get full text

Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base by Mantripragada, Kalyan C, Hamid, Fatima, Shafqat, Hammad, Olszewski, Adam J

“…Management of resected gallbladder cancer relies on single-arm trials and retrospective observations. Our objective was to evaluate adjuvant therapy in a…”
Get full text

Human immunodeficiency virus‐associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base by Olszewski, Adam J., Fallah, Jaleh, Castillo, Jorge J.

“…BACKGROUND Antiviral therapy has altered the prognosis of patients with human immunodeficiency virus (HIV)‐associated non‐Hodgkin lymphoma (NHL), but patterns…”
Get full text

Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomas by Olszewski, Adam J., Ollila, Thomas, Reagan, John L.

“…Summary In aggressive lymphomas, discrepancies in survival reported from experimental and observational studies may reflect selective non‐enrolment of…”
Get full text

Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population‐Based Analysis by Olszewski, Adam J., Treon, Steven P., Castillo, Jorge J.

“…Introduction. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM) is a rare lymphoma affecting older patients. Its management largely relies on small…”
Get full text

Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response‐specific osteo‐mesenchymal profiles by Treaba, Diana O., Bonal, Dennis M., Chorzalska, Anna, Castillo‐Martin, Mireia, Oakes, Alissa, Pardo, Makayla, Petersen, Max, Schorl, Christoph, Hopkins, Kelsey, Melcher, Dean, Zhao, Ting C., Liang, Olin, So, Eui‐Young, Reagan, John, Olszewski, Adam J., Butera, James, Anthony, Douglas C., Rintels, Peter, Quesenberry, Peter, Dubielecka, Patrycja M.

“…Summary While the bone marrow (BM) microenvironment is significantly remodelled in acute myeloid leukaemia (AML), molecular insight into AML‐specific…”
Get full text

Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD by McKenna, Marshall, Epperla, Narendranath, Ghobadi, Armin, Liu, Jieqi, Lazaryan, Aleksandr, Ibrahim, Uroosa, Jacobson, Caron A., Naik, Seema G., Nastoupil, Loretta, Chowdhury, Sayan Mullick, Voorhees, Timothy J., Jacobs, Miriam T., Farooq, Umar, Osman, Keren, Olszewski, Adam J., Ahmed, Sairah, Evens, Andrew M.

“…Summary The use of CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy for relapsed/refractory solid organ transplantation (SOT)‐related post‐transplant…”
Get full text

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma by Hsu, Andrew, Huntington, Kelsey E., De Souza, Andre, Zhou, Lanlan, Olszewski, Adam J., Makwana, Nirav P., Treaba, Diana O., Cavalcante, Ludimila, Giles, Francis J., Safran, Howard, El-Deiry, Wafik S., Carneiro, Benedito A.

“…GSK-3β is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3β blockade downregulates the NF-κB pathway, modulates immune…”
Get full text

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study by Schumacher, Andrew, Sikov, William M, Quesenberry, Matthew I, Safran, Howard, Khurshid, Humera, Mitchell, Kristen M, Olszewski, Adam J

“…Informed consent forms (ICFs) for oncology clinical trials have grown increasingly longer and more complex. We evaluated objective understanding of critical…”
Get full text

Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue by Olszewski, Adam J., MD, Desai, Amrita, MD, MPH

“…Purpose To determine the factors associated with the use of radiation therapy and associated survival outcomes in early-stage marginal zone lymphoma of the…”
Get full text

When B cells rebuff bispecifics by Olszewski, Adam J.

Get full text

Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study by Epperla, Narendranath, Welkie, Rina Li, Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem, Shea, Lauren, Anampa-Guzmán, Andrea, Oh, Timothy S, Reaves, Heather, Tavakkoli, Montreh, Lindsey, Kathryn, Greenwell, Irl Brian, Hansinger, Emily, Thomas, Colin, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Christian, Beth, Barta, Stefan K, Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L, Herrera, Alex F, Grover, Natalie S, Olszewski, Adam J

“…Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However,…”
Get full text

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia by Chorzalska, Anna, Ahsan, Nagib, Rao, R. Shyama Prasad, Roder, Karim, Yu, Xiaoqing, Morgan, John, Tepper, Alexander, Hines, Steven, Zhang, Peng, Treaba, Diana O., Zhao, Ting C., Olszewski, Adam J., Reagan, John L., Liang, Olin, Gruppuso, Philip A., Dubielecka, Patrycja M.

“…The introduction of tyrosine kinase inhibitors (TKI) has transformed chronic myeloid leukemia (CML) into a chronic disease with long‐term survival exceeding…”
Get full text

Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study by Ali, Shihab, Olszewski, Adam J.

“…Abstract We compared survival outcomes and rates of secondary non-Hodgkin lymphoma (NHL) in 28 323 patients with nodular lymphocyte predominant (NLPHL) and…”
Get full text

Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study by Grover, Natalie S., Annunzio, Kaitlin, Watkins, Marcus, Torka, Pallawi, Karmali, Reem, Anampa-Guzmán, Andrea, Oh, Timothy S., Reves, Heather, Tavakkoli, Montreh, Hansinger, Emily, Christian, Beth, Thomas, Colin, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Shouse, Geoffrey, Olszewski, Adam J., Epperla, Narendranath

“…Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of…”
Get full text

Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis by Olszewski, Adam J, Gutman, Roee, Eaton, Charles B

Get full text

Meet the Burkitts: a dark zone family by Olszewski, Adam J.

Get full text